- Tytuł:
- 118O Definitive results for NSCLC and bladder cancer cohorts in the phase IIa trial of visugromab (CTL-002) in advanced/metastatic anti-PD/PD-L1 relapsed/refractory solid tumors (GDFATHER-trial)
- Autorzy:
- Źródło:
- In Immuno-Oncology and Technology December 2023 20 Supplement
Czasopismo naukowe